Dramatic improvement in refractory myasthenia gravis with eculizumab treatment: a case report

J Neurol. 2024 May;271(5):2902-2905. doi: 10.1007/s00415-024-12245-z. Epub 2024 Feb 23.

Authors

Kana Ohnari^#¹, Tomoyo Hashimoto^#², Yukio Iwanaka¹, Keiko Ohnari¹, Hiroaki Adachi¹, Kazumasa Okada¹

Affiliations

¹ Department of Neurology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
² Department of Neurology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan. h-tomoyo@med.uoeh-u.ac.jp.

^# Contributed equally.

PMID: 38393426
DOI: 10.1007/s00415-024-12245-z

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antibodies, Monoclonal, Humanized* / pharmacology
Antibodies, Monoclonal, Humanized* / therapeutic use
Complement Inactivating Agents / pharmacology
Complement Inactivating Agents / therapeutic use
Female
Humans
Male
Middle Aged
Myasthenia Gravis* / drug therapy
Treatment Outcome

Substances

eculizumab
Antibodies, Monoclonal, Humanized
Complement Inactivating Agents